Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology

Liver Cancer

Arkansas

Little Rock : Univ Of Ark For Med Sci

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Little Rock : Univ Of Ark For Med Sci

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

California

Duarte : City of Hope New!

A Phase 1 Open Label/Phase 2 Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients with Advanced Hepatocellular Carcinoma

Duarte : City of Hope New!

A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere (Yittrium-90 Glass Microspheres): A HDE Treatment Use Protocol

Duarte : City of Hope New!

PHII-83 NCI #7792: A Phase II Trial of Dasatinib (BMS354825) in Advanced Hepatocellular Carcinoma

Duarte : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Loma Linda : Loma Linda University Cancer Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Loma Linda : Loma Linda University Cancer Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Los Angeles : Ucla

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Los Angeles : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Los Angeles : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

San Diego : Sharp Clinical Oncology Research

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

San Diego : Sharp Clinical Oncology Research

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

San Francisco : California Pacific Medical Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

San Francisco : California Pacific Medical Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Delaware

Newark : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Florida

Gainesville : University Of Florida

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Miami : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Vero Beach : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Georgia

Atlanta : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Hawaii

Honolulu : Hawaii Medical Center East

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Illinois

Chicago : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Chicago : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Peoria : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Indiana

South Bend : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Iowa

Iowa City : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Kentucky

Louisville : James Graham Brown Cancer Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Louisville : James Graham Brown Cancer Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Massachusetts

Boston : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Michigan

Ann Arbor : University Of Michigan

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Ann Arbor : University Of Michigan

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Detroit : Wayne State University

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Detroit : Henry Ford Hospital

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Detroit : Henry Ford Hospital

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Detroit : Wayne State University

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Minnesota

Rochester : Mayo Clinic Rochester

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Missouri

St. Louis : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Nebraska

Omaha : University Of Nebraska Medical Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Omaha : University Of Nebraska Medical Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

New Jersey

Hackensack : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

New York

Bronx : Biomedical Research Alliance of New York

Advanced Hepatocellular Carcinoma (Liver Cancer)

Buffalo : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

New York : Mount Sinai Medical Center

A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma

New York : Biomedical Research Alliance of New York

Advanced Hepatocellular Carcinoma (Liver Cancer)

New York : Columbia University Medical Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

New York : Mount Sinai School Of Medicine

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

New York : Columbia University Medical Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

New York : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

North Carolina

Durham : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Ohio

Columbus : Ohio State University

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Oregon

Portland : Oregon Health & Sci Univ

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Portland : Oregon Health & Sci Univ

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Pennsylvania

Hershey : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Philadelphia : Thomas Jefferson Univ.

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Philadelphia : Thomas Jefferson Univ.

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Philadelphia : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Philadephia : University Of Pennsylvania

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Philadephia : University Of Pennsylvania

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Pittsburgh : Upmc

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Tennessee

Nashville : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Texas

Dallas : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Dallas : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Houston : University Of Texas

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 In Patients With Primary Liver Cancer

Houston : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

San Antonio : The University Of Texas Health Science Center

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

San Antonio : The University Of Texas Health Science Center

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Virginia

Charlottesville : University Of Virginia

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Richmond : Mcguire Dvamc

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Richmond : Mcguire Dvamc

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Wisconsin

Madison : University Of Wisconsin

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Madison : University Of Wisconsin

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Milwaukee : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

China

Beijing : Research Site:

A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer

Hong Kong : Research Site:

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

France

Marseille : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Montpellier Cedex 5 : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Reims Cedex : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Rennes : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Villejuif : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Hong Kong

Hong Kong : Research Site:

A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer.

Kowloon : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Shatin : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Korea, Republic of

Gyeonggi-Do : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Seoul : Research Site:

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Seoul : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Seoul : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Seoul : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Kuala Lumpur

Cheras : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Negeri Sembilan

Nilai : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Philippines

Cebu City : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Davo City : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Manila : Research Site:

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Quezon : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Singapore

Singapore : Research Site:

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Singapore : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Singapore : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Taiwan

Kueishan : Research Site:

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Kueishan : Research Site:

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Tainan : Research Site:

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Tainan : Research Site:

A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer

Tainan : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Taipei : Research Site:

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Taipei : Research Site:

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Taipei : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Taipei City : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Thailand

Songkhla : Research Site:

A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer

United Kingdom

Birmingham : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

London : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

Northwood : Local Institution

Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer